Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their 14-month progress using Pyrilutamide and Minoxidil for hair loss, noting improvement and no side effects with these treatments, unlike their negative experiences with Finasteride and RU58841. They emphasized the importance of consistent application for seeing results.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

A 28-year-old male is experiencing hair loss, itching, soreness, and numbness on the scalp, with symptoms including dry, brittle hair and scalp irritation. Treatments tried include Nizoral, salt water, various oils, and antihistamines, with limited success; a chemist suggested a possible fungal infection, while a doctor suspected male pattern baldness.

Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.

A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.

A user who was losing their hair and found an effective solution; they asked for opinions on it and discussed treatments such as Minoxidil, Finasteride, and RU58841, as well as SMP.

A 25-year-old male experienced significant hair loss due to telogen effluvium and androgenetic alopecia. He began using finasteride, minoxidil, and vitamins, seeing some regrowth but remains worried about hair density.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

The conversation discusses the scalp tension theory as a potential factor in hair loss, alongside DHT, inflammation, and other mechanisms. Treatments mentioned include finasteride, minoxidil, and botox injections, with some users exploring additional methods due to varying effectiveness.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.

A user is starting a topical finasteride treatment for diffuse patterned alopecia, having previously used minoxidil without success. They are cautious about side effects and have chosen topical over oral finasteride, while also using Nizoral and biotin in their routine.

The conversation discusses how to mix pyrilutamide for hair loss treatment, suggesting a mixture of 500mg pyrilutamide with 70% ethanol and 30% propylene glycol, and a potential application dose of 1mL. The user has not personally used pyrilutamide but has researched its preparation and application based on others' experiences.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

User discusses using C60 serum with microneedling at 1.75mm and asks if it's safe. Current routine includes daily Pyril on temples, weekly microneedling, and C60 serum on non-Pyril days.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.

An 18-year-old diagnosed with male pattern baldness is using probiotics, saw palmetto, pumpkin seed oil, soy isoflavones, biotin, fish oil, quercetin, a multivitamin, and ketoconazole shampoo. Replies suggest these methods are ineffective and recommend finasteride, minoxidil, and a derma roller.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A user shared a 9-month hair loss treatment update using scalp micropigmentation (SMP), finasteride, minoxidil, derma pen, ketoconazole shampoo, and low-level laser therapy (LLLT), with plans for a hair transplant. Another person suggested increasing the dosage of finasteride and minoxidil and using a derma roller weekly.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

The conversation humorously discusses hair loss treatments, mentioning spironolactone and cyproterone acetate. It reflects a sense of frustration and satire about the effectiveness of these treatments.

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

My hairline, I am only 23. This conversation is about a user's experience with treatments for androgenic alopecia, including finasteride, dutasteride, RU, minoxidil, progesterone, melatonin, LLLT, oral minoxidil, and Pyrilutamide. They have tried many treatments over the course of two years without seeing much success, and they are considering getting a hair system as a last resort.

The user experienced significant hair regrowth after 9 months of using finasteride, with minimal use of minoxidil. They reported no side effects and emphasized patience and consistency in their treatment routine.